Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsatran
Drug: valsartan
Drug: placebo to valsartan
Drug: placebo to sacubitril/valsartan

First Posted Date: 2017-10-03

Last Posted Date: 2024-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT03300427

Locations: 🇫🇮
Novartis Investigative Site, Turku, Finland

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: CJM112
Other: Placebo to CJM112

First Posted Date: 2017-10-03

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT03299686

Locations: 🇸🇰
Novartis Investigative Site, Spisska Nova Ves, Slovakia

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

Phase 2

Terminated

Conditions: Painful Diabetic Neuropathy

Interventions: Drug: EMA401
Drug: Placebo

First Posted Date: 2017-09-29

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT03297294

Locations: 🇬🇧
Novartis Investigative Site, Oldham, United Kingdom

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: VAY736
Drug: Placebo
Drug: Standard of Care (SoC)

First Posted Date: 2017-09-19

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT03287414

Locations: 🇬🇧
Novartis Investigative Site, High Heaton, Newcastle Upon Tyne, United Kingdom

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Placebo
Drug: Midostaurin

First Posted Date: 2017-09-12

Last Posted Date: 2023-04-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT03280030

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Biological: LNA043
Other: Placebo

First Posted Date: 2017-09-07

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT03275064

Locations: 🇩🇰
Novartis Investigative Site, Hvidovre, Denmark

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Phase 2

Completed

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: crizanlizumab

First Posted Date: 2017-08-29

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT03264989

Locations: 🇺🇸
Childrens Healthcare of Atlanta ., Atlanta, Georgia, United States
🇺🇸
University of Maryland Medical Ctr, Baltimore, Maryland, United States
🇺🇸
East Carolina University East Carolina University, Greenville, North Carolina, United States

and more 8 locations

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: AIN457 150 mg
Biological: Placebo
Biological: GP2017 (adalimumab biosimilar)

First Posted Date: 2017-08-23

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 859

Registration Number: NCT03259074

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2017-08-22

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT03257358

Locations: 🇺🇸
Novartis Investigative Site, Neenah, Wisconsin, United States

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Indacaterol maleate
Drug: Indacaterol acetate
Drug: Placebo

First Posted Date: 2017-08-22

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03257995

Locations: 🇺🇸
Novartis Investigative Site, El Paso, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy